[{"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.", "fullTimeEmployees": 711, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher R. Anzalone Ph.D.", "age": 56, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2025, "totalPay": 2219569, "exercisedValue": 2948360, "unexercisedValue": 1465915}, {"maxAge": 1, "name": "Mr. Daniel J. Apel", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2025, "totalPay": 1044095, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  O'Brien J.D., PharmD", "age": 61, "title": "COO & Secretary", "yearBorn": 1964, "fiscalYear": 2025, "totalPay": 1051195, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James C. Hamilton M.D., MBA", "age": 46, "title": "Chief Medical Officer and Head of R&D", "yearBorn": 1979, "fiscalYear": 2025, "totalPay": 987213, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark M. Davis Ph.D.", "title": "Founder and Founder & Director of Insert Therapeutics Inc & Calando", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Lovy", "title": "Director of Communications", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruce D. Given M.D.", "age": 71, "title": "Chief Medical Scientist", "yearBorn": 1954, "fiscalYear": 2025, "totalPay": 486308, "exercisedValue": 5934362, "unexercisedValue": 6159876}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 71, "title": "Head of Toxicology & VP", "yearBorn": 1954, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Aaron  Tan", "title": "Head of Tax", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 3, "shareHolderRightsRisk": 1, "overallRisk": 3, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1767139200, "irWebsite": "http://www.arrowheadresearch.com/invest.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 63.86, "open": 63.71, "dayLow": 62.1, "dayHigh": 64.59, "regularMarketPreviousClose": 63.86, "regularMarketOpen": 63.71, "regularMarketDayLow": 62.1, "regularMarketDayHigh": 64.59, "payoutRatio": 0.0, "beta": 1.222, "trailingPE": 39.743748, "forwardPE": -14.798697, "volume": 2521411, "regularMarketVolume": 2521411, "averageVolume": 3188530, "averageVolume10days": 4930670, "averageDailyVolume10Day": 4930670, "bid": 63.35, "ask": 63.91, "bidSize": 13, "askSize": 13, "marketCap": 8904646656, "fiftyTwoWeekLow": 9.57, "fiftyTwoWeekHigh": 76.76, "allTimeHigh": 2925.0, "allTimeLow": 1.2, "priceToSalesTrailing12Months": 8.162055, "fiftyDayAverage": 66.8439, "twoHundredDayAverage": 36.647476, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 8682375168, "profitMargins": 0.18540001, "floatShares": 122029652, "sharesOutstanding": 140032190, "sharesShort": 11150281, "sharesShortPriorMonth": 9626302, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0796, "heldPercentInsiders": 0.038039997, "heldPercentInstitutions": 0.84282, "shortRatio": 4.14, "shortPercentOfFloat": 0.1112, "impliedSharesOutstanding": 140032190, "bookValue": 4.137, "priceToBook": 15.371041, "lastFiscalYearEnd": 1759190400, "nextFiscalYearEnd": 1790726400, "mostRecentQuarter": 1767139200, "netIncomeToCommon": 202264992, "trailingEps": 1.6, "forwardEps": -4.297, "lastSplitFactor": "1:10", "lastSplitDate": 1321488000, "enterpriseToRevenue": 7.958, "enterpriseToEbitda": 26.662, "52WeekChange": 2.386002, "SandP52WeekChange": 0.14684999, "quoteType": "EQUITY", "currentPrice": 63.59, "targetHighPrice": 110.0, "targetLowPrice": 35.0, "targetMeanPrice": 81.36364, "targetMedianPrice": 80.0, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 914710016, "totalCashPerShare": 6.532, "ebitda": 325649984, "totalDebt": 698163008, "quickRatio": 3.263, "currentRatio": 3.38, "totalRevenue": 1090980992, "debtToEquity": 124.074, "revenuePerShare": 7.975, "returnOnAssets": 0.14352, "returnOnEquity": 0.75496, "grossProfits": 1090980992, "freeCashflow": 170725872, "operatingCashflow": 339304992, "revenueGrowth": 104.613, "grossMargins": 1.0, "ebitdaMargins": 0.29849002, "operatingMargins": 0.15456, "financialCurrency": "USD", "symbol": "ARWR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "regularMarketChangePercent": -0.422801, "regularMarketPrice": 63.59, "corporateActions": [], "postMarketTime": 1771625376, "regularMarketTime": 1771621202, "exchange": "NMS", "messageBoardId": "finmb_203142", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Arrowhead Pharmaceuticals, Inc.", "longName": "Arrowhead Pharmaceuticals, Inc.", "postMarketChangePercent": 0.0, "postMarketPrice": 63.59, "postMarketChange": 0.0, "regularMarketChange": -0.27, "regularMarketDayRange": "62.1 - 64.59", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 3188530, "fiftyTwoWeekLowChange": 54.02, "fiftyTwoWeekLowChangePercent": 5.6447234, "fiftyTwoWeekRange": "9.57 - 76.76", "fiftyTwoWeekHighChange": -13.170002, "fiftyTwoWeekHighChangePercent": -0.17157376, "fiftyTwoWeekChangePercent": 238.6002, "earningsTimestamp": 1770325200, "earningsTimestampStart": 1778533200, "earningsTimestampEnd": 1778533200, "earningsCallTimestampStart": 1770327000, "earningsCallTimestampEnd": 1770327000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 1.6, "epsForward": -4.297, "epsCurrentYear": -3.23909, "priceEpsCurrentYear": -19.632057, "fiftyDayAverageChange": -3.2539024, "fiftyDayAverageChangePercent": -0.04867912, "twoHundredDayAverageChange": 26.942524, "twoHundredDayAverageChangePercent": 0.73518085, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.7 - Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 756052200000, "cryptoTradeable": false, "displayName": "Arrowhead Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]